Lymphoid Leukemia

17 registered clinical trials studyying Lymphoid Leukemia — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study NCT07292272	University of Nebraska	Phase 2
Active Not Recruiting	Integrated Actionable Aging Assessment for Cancer Patients Pilot NCT05871008	University of Colorado, Denver	N/A
Recruiting	Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy NCT05865301	Stanford University	—
Active Not Recruiting	Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL NCT05507827	Stanford University	Phase 1
Completed	Healthy Bones, Healthy Life: Habitual Physical Activity on Bone & Metabolic Health in Pediatric Cancer Survivo NCT04472286	University of Nebraska	—
Terminated	Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or NCT04155840	University of Washington	Phase 2
Completed	Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia NCT03575325	H. Lee Moffitt Cancer Center and Research Institute	Phase 2
Completed	Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients NCT03613727	Virginia Commonwealth University	Phase 2
Suspended	Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemi NCT02462265	Oshadi Drug Administration	Phase 2
Completed	Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery NCT02955043	University of Wisconsin, Madison	N/A
Completed	Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation NCT02719821	University of Wisconsin, Madison	N/A
Completed	Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis NCT02593123	Virginia Commonwealth University	Phase 2
Completed	Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreate NCT01754857	University of Wisconsin, Madison	Phase 2
Terminated	Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies NCT01643603	Barbara Ann Karmanos Cancer Institute	Phase 1
Unknown	My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia NCT00801580	University of Bologna	Phase 2
Completed	Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Mye NCT00469729	Gamida Cell -Teva Joint Venture Ltd.	Phase 2 / Phase 3
Completed	T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies NCT00683046	University of Chicago	Phase 2